Codexis, Inc.
Redwood City, CA 94063
Research Tool facilitates safe drug development.
With Codex(TM) MicroCyp Plate, pharmaceutical companies can rapidly identify and synthesize drug metabolites and novel drug lead candidates. Research tool is based on specific cytochrome enzyme, 102A1, which metabolizes fatty acids in microbe. Launch of product expands research product family, adding metabolite screening and synthesis as well as lead diversification to full suite of tools for...
Read More »Codexis to Present at the Jefferies and Pacific Crest Conferences
REDWOOD CITY, Calif., Feb. 8, 2011 - Codexis, Inc. (Nasdaq: CDXS) today announced the company will present at the Jefferies Global Clean Technology Conference, to be held in New York, NY on February 23-24, 2011. The presentation is scheduled for February 23 at 1:00 p.m. Eastern Time. The company will also present at the Pacific Crest Clean Technology Conference, to be held in San Francisco, CA on...
Read More »DSM and Codexis Sign Enzyme Supply Agreement
PARSIPPANY, N.J. and REDWOOD CITY, Calif., Jan. 12, 2011 - DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, and Codexis, Inc. (Nasdaq:CDXS) today announce signing of an enzyme supply agreement. The agreement grants DSM rights to use Codexis' custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based...
Read More »Codexis to Present at Piper Conference
Codexis To Present at the Piper Jaffray Clean Technology & Renewables Conference REDWOOD CITY, Calif., Dec. 20, 2010 - Codexis, Inc. (Nasdaq: CDXS) today announced the company will present at the Piper Jaffray Clean Technology & Renewables Conference, to be held in New York, NY on January 12, 2011. The presentation will be made by Robert Lawson, Senior Vice President and Chief Financial Officer,...
Read More »Codexis to Present at Baird Conference
REDWOOD CITY, Calif., Nov. 4, 2010 -- Codexis, Inc. (Nasdaq: CDXS) today announced that the company will participate in the Baird Clean Technology Conference, Nov. 30-Dec. 1, 2010 in San Francisco, CA. Alan Shaw, Ph.D., President and Chief Executive Officer, will give a company presentation on November 30 at 4:45 pm Pacific Time. An audio webcast and replay will be available in the Investor...
Read More »Codexis Acquires Maxygen Directed Evolution Intellectual Property Portfolio; Biofuels Payments to Maxygen End, Codexis Fields of Use Expand
REDWOOD CITY, Calif., Oct. 28 -- Codexis, Inc. (Nasdaq: CDXS) today announced that the company has acquired the directed evolution intellectual property portfolio of Maxygen, Inc. (Nasdaq: MAXY) for $20 million in cash. With this transaction, Codexis no longer has any obligations to make payments to Maxygen, including potential royalties, relating to biofuels and other energy products. The...
Read More »Codexis to Present at the Goldman Sachs Clean Energy Conference
REDWOOD CITY, Calif., Oct. 19 - Codexis, Inc. (Nasdaq: CDXS) today announced the company will participate in the Goldman Sachs Fifth Annual Clean Energy Conference in New York, NY on November 10-11, 2010. Alan Shaw, Ph.D., President and Chief Executive Officer, will appear on a panel titled Biomass Conversion: Back from the Brink , scheduled for November 10 at 1:30 pm Eastern Time. A webcast and...
Read More »Codexis to Present at Wedbush and Credit Suisse Investor Conferences in September
REDWOOD CITY, Calif., Aug. 30 - Codexis, Inc. (NASDAQ:CDXS) today announced that the company will participate in the Wedbush Morgan Clean Technology and Industrial Growth Conference, September 14-15, 2010 in San Francisco, CA. Alan Shaw, Ph.D., President and Chief Executive Officer, will give a company presentation on September 14 at 3:35pm Pacific Time. The company will also participate in the...
Read More »Research Tool facilitates safe drug development.
With Codex(TM) MicroCyp Plate, pharmaceutical companies can rapidly identify and synthesize drug metabolites and novel drug lead candidates. Research tool is based on specific cytochrome enzyme, 102A1, which metabolizes fatty acids in microbe. Launch of product expands research product family, adding metabolite screening and synthesis as well as lead diversification to full suite of tools for...
Read More »Codexis Acquires BioCatalytics
Merger Creates Global Leadership in Biocatalyst Design, Synthesis and Use REDWOOD CITY, Calif., July 19 / -- Codexis, Inc., a private biotechnology company and leading developer of clean manufacturing technologies, today announced it has acquired BioCatalytics, Inc., Pasadena, CA. BioCatalytics is a private company that has produced custom and off-the-shelf enzymes used in chemical process...
Read More »